Kevin Patrick Danahy - Sep 23, 2022 Form 4 Insider Report for Pulse Biosciences, Inc. (PLSE)

Role
Chief Executive Officer
Signature
/s/ Kenneth B. Stratton, as Attorney-in-Fact
Stock symbol
PLSE
Transactions as of
Sep 23, 2022
Transactions value $
$0
Form type
4
Date filed
9/27/2022, 05:46 PM
Previous filing
Mar 24, 2023
Next filing
Oct 3, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PLSE Stock Option (right to buy) Award +450K 450K Sep 23, 2022 Common Stock 450K $1.53 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option was granted on September 23, 2022 under the Issuer's 2017 Equity Incentive Plan and pursuant to an amendment to the Reporting Person's employment agreement. The shares will vest in four equal annual installments on each of the first four annual anniversaries of the grant date, subject to the Reporting Person's continued service through each vesting date.
F2 Not applicable.